{"id":877795,"date":"2025-08-21T07:04:50","date_gmt":"2025-08-21T11:04:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/"},"modified":"2025-08-21T07:04:50","modified_gmt":"2025-08-21T11:04:50","slug":"i-mab-to-participate-in-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/","title":{"rendered":"I-Mab to Participate in September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ROCKVILLE, Md., Aug.  21, 2025  (GLOBE NEWSWIRE) &#8212; I-Mab (NASDAQ: IMAB) (the \u201cCompany\u201d), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab\u2019s management team will participate in the following upcoming investor conferences in September, 2025:<\/p>\n<p align=\"justify\">Conference details are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Cantor Global Healthcare Conference<\/strong><br \/>\n        <br \/>Format: One-on-one meetings<br \/>Date: September 3-5, 2025<\/p>\n<p align=\"justify\">\n        <strong>H.C. Wainwright 27<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Global Investment Conference<\/strong><br \/>\n        <br \/>Format: Company presentation and one-on-one meetings<br \/>Date: Wednesday, September 10, 2025<br \/>Time: 9:30 AM ET<br \/>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1BGzEvJ-cloT5SyZuoO831bfP_9FQMwbhF2P1gzXBxyK6HX7j86KSPUoshRnIlO6GBMsTwNsy2WAQnRkZBcsJclFh97WDG9jhOt-OKwxrcEhXpmeFS8BDg4mk8vAhUmO6_tLs2KZbbhzpWYv6NBK4g==\" rel=\"nofollow\" target=\"_blank\">Here<\/a><\/p>\n<p align=\"justify\">The webcast of the company presentation will be accessible from News &amp; Events page of the\u00a0I-Mab\u00a0website for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About I-Mab<\/strong>\n      <\/p>\n<p align=\"justify\">I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company\u2019s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-VXOnj8bleDeQxfo686pS0VC0VEl9MZaucNDnPrMIdnkPG6O4MXQ-7UL4vgw7APo-wkcr0wYwWI5cPWdwI4wEyj40qZLNUprk0wHubjv0ppsxXN_ooCXKRnILt25UJF5\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.i-mabbiopharma.com<\/a> and follow us on LinkedIn.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>I-Mab Investor &amp; Media Contacts<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">PJ Kelleher<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">LifeSci Advisors<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">+1-617-430-7579<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <a href=\"mailto:pkelleher@lifesciadvisors.com\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">IR@imabbio.com<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjFlYjU3MjItNDMzMC00YzgyLTkxMDItMzJmNzExYTk4ZjQ4LTUwMDEyNTAyOS0yMDI1LTA4LTIxLWVu\/tiny\/I-Mab-Biopharma.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; I-Mab (NASDAQ: IMAB) (the \u201cCompany\u201d), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab\u2019s management team will participate in the following upcoming investor conferences in September, 2025: Conference details are as follows: Cantor Global Healthcare Conference Format: One-on-one meetingsDate: September 3-5, 2025 H.C. Wainwright 27 th Annual Global Investment Conference Format: Company presentation and one-on-one meetingsDate: Wednesday, September 10, 2025Time: 9:30 AM ETWebcast Link: Here The webcast of the company presentation will be accessible from News &amp; Events page of the\u00a0I-Mab\u00a0website for 90 days. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;I-Mab to Participate in September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-877795","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>I-Mab to Participate in September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"I-Mab to Participate in September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; I-Mab (NASDAQ: IMAB) (the \u201cCompany\u201d), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab\u2019s management team will participate in the following upcoming investor conferences in September, 2025: Conference details are as follows: Cantor Global Healthcare Conference Format: One-on-one meetingsDate: September 3-5, 2025 H.C. Wainwright 27 th Annual Global Investment Conference Format: Company presentation and one-on-one meetingsDate: Wednesday, September 10, 2025Time: 9:30 AM ETWebcast Link: Here The webcast of the company presentation will be accessible from News &amp; Events page of the\u00a0I-Mab\u00a0website for 90 days. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development &hellip; Continue reading &quot;I-Mab to Participate in September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T11:04:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"I-Mab to Participate in September Investor Conferences\",\"datePublished\":\"2025-08-21T11:04:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/\"},\"wordCount\":265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/\",\"name\":\"I-Mab to Participate in September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==\",\"datePublished\":\"2025-08-21T11:04:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-participate-in-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"I-Mab to Participate in September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"I-Mab to Participate in September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"I-Mab to Participate in September Investor Conferences - Market Newsdesk","og_description":"ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) &#8212; I-Mab (NASDAQ: IMAB) (the \u201cCompany\u201d), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab\u2019s management team will participate in the following upcoming investor conferences in September, 2025: Conference details are as follows: Cantor Global Healthcare Conference Format: One-on-one meetingsDate: September 3-5, 2025 H.C. Wainwright 27 th Annual Global Investment Conference Format: Company presentation and one-on-one meetingsDate: Wednesday, September 10, 2025Time: 9:30 AM ETWebcast Link: Here The webcast of the company presentation will be accessible from News &amp; Events page of the\u00a0I-Mab\u00a0website for 90 days. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development &hellip; Continue reading \"I-Mab to Participate in September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-21T11:04:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"I-Mab to Participate in September Investor Conferences","datePublished":"2025-08-21T11:04:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/"},"wordCount":265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/","name":"I-Mab to Participate in September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==","datePublished":"2025-08-21T11:04:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNTgzMSM3MTA5MTY5IzUwMDEyNTAyOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-participate-in-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"I-Mab to Participate in September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=877795"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/877795\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=877795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=877795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=877795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}